AgomAb Therapeutics

piggy bank cash money pay

Biotech

Agomab uses $100M series C to push Crohn's drug through phase 2

A week after entering its lead asset into a phase 2 trial, Agomab has secured $100 million in series C financing to power up its pipeline.

James Waldron Oct 11, 2023 8:50am

topic report

Fierce Biotech's 2022 Fierce 15

Sep 12, 2022 3:00am

money private equity venture capital investment cash dollar sign investor

Pfizer jumps into bed with Agomab, leading series B extension

Jul 13, 2022 10:10am

Person and parachite after landing in snow

CRISPR cans R&D chief in SEC filing—Chutes & Ladders

Dec 22, 2021 9:30am

AgomAb

AgomAb raises $74M to develop regenerative pathway modulators

Mar 10, 2021 5:00am